Acromegaly is a chronic systemic disease with many complications and is associated with
increased mortality when not adequately treated. Substantial advances in acromegaly …

Acromegaly is characterized by increased release of growth hormone and, consequently,
insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to …

Objective The aim of the Acromegaly Consensus Group was to revise and update the
consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013 …

Acromegaly is a rare disease, caused largely by a growth hormone (GH) pituitary adenoma.
Incidence is higher than previously thought. Due to increased morbidity and mortality, if not …

Excess levels of circulating GH and IGF-1 in acromegaly have deleterious effects on a wide
range of physiologic processes and tissues. GH levels directly reflect somatotroph tumor …

Neurocognitive and psychological dysfunctions associated with pituitary adenomas (PAs)
are clinically relevant, though probably under-reported. The aim of the current review is to …

Objective Acromegaly is associated with somatic disfigurements which impair self-
perception of well-being and quality of life. Nowadays, limited data are available on the …

Acromegaly is a rare disease with prevalence of approximately 60 cases per million, slight
female predominance and peak onset in adults in the fourth decade. Clinical diagnosis is …

Context Insight into the current landscape of patient-reported outcome (PRO) measures
(PROM) and differences between PROs and conventional biochemical outcomes is pivotal …

Pegvisomant, the first and currently only clinically available growth hormone receptor
antagonist, is an effective therapeutic option for the medical treatment of acromegaly, a rare …